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Background: Patients with mixed hyperlipidemia usually are in need of combination therapy to achieve
low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) target values for reduction of cardiovascular risk.
This study investigated the efficacy and safety of adding a new hypolipidemic agent, coenzyme A (CoA) to stable
statin therapy in patients with mixed hyperlipidemia.
Methods: In this multi-center, 8-week, double-blind study, adults who had received ≥8 weeks of stable statin
therapy and had hypertriglyceridemia (TG level at 2.3-6.5 mmol/L) were randomized to receive CoA 400 U/d or
placebo plus stable dosage of statin. Efficacy was assessed by the changes in the levels and patterns of lipoproteins.
Tolerability was assessed by the incidence and severity of adverse events (AEs).
Results: A total of 304 patients with mixed hyperlipidemia were randomized to receive CoA 400 U/d plus statin or
placebo plus statin (n = 152, each group). After treatment for 8 weeks, the mean percent change in TG was
significantly greater with CoA plus statin compared with placebo plus statin (−25.9% vs −4.9%, respectively; p = 0.0003).
CoA plus statin was associated with significant reductions in TC (−9.1% vs −3.1%; p = 0.0033), LDL-C (−9.9% vs
0.1%; p = 0.003), and non- high-density lipoprotein cholesterol (−13.5% vs −5.7%; p = 0.0039). There was no significant
difference in the frequency of AEs between groups. No serious AEs were considered treatment related.
Conclusions: In these adult patients with persistent hypertriglyceridemia, CoA plus statin therapy improved TG
and other lipoprotein parameters to a greater extent than statin alone and has no obviously adverse effect.
Trial registration: Current Controlled Trials ClinicalTrials.gov ID NCT01928342.
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Hyperlipidemia plays important roles in the development
and progression of atherosclerosis and coronary artery dis-
ease (CAD) [1,2]. Modulating lipid levels mostly focused
on the control of low-density lipoprotein cholesterol
(LDL-C) with 3-hydroxy-3-methylglutaryl coenzyme A re-
ductase inhibitors (statins) has been shown to be clearly
efficacious in the treatment and prevention of CAD [3].* Correspondence: xuantianming2012@gmail.com
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stated.However, despite increasing use of statins, even in optimal
doses to achieve target LDL-C reduction, considerable
residual risk remains. Such risk resides in elevated levels
of triglycerides (TG), and subnormal levels of atheropro-
tective high-density lipoprotein cholesterol (HDL-C), and
treatment combining a statin with another lipid-modifying
agent may be required for mixed hyperlipidemia [4-7].
However, combination therapies, including fibrates,
niacin, or omega-3 fatty acids (OM3-FAs) in addition to
statin treatment, are often recommended but less often
used due to concerns with cost, tolerability and complianceThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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phokinase (CPK) levels, and more serious complications
such as myositis and rhabdomyolysis are more frequent
when fibrates are combining used with a statin [9-11].
Many patients have difficulty tolerating niacin because of
relatively benign but troublesome adverse events, namely,
flushing, and niacin may exacerbate hyperuricemia, glu-
cose intolerance, and hepatic dysfunction when combining
with a statin [12-14]. OM3-FAs have been shown their well
tolerability as an adjunct to statin therapy in numerous
studies [15-17]. However, it was also reported that OM3-
FAs can produce an increase in LDL in some patients
[17-20]. So, there is ongoing research into new, safer and
more effective agents to be used alone or in combination
with existing cardiovascular drugs [21].
Coenzyme A (CoA) functions as an acyl group carrier
and assists in transferring fatty acids from the cytoplasm
to mitochondria [22]. It is also involved in the oxidation
and catabolism of fatty acids [23,24]. Previous researches
revealed that insufficiency of CoA in vivo influenced
fatty acid β-oxidation catabolism and impaired clearance
of TG from plasma [23,24], which was supposed to be
one plausible reason resulting in type IIb and type IV
hyperlipoproteinemia. Moreover, studies on animals have
given evidence to prove that supplement of CoA had nor-
malizing activity on plasma lipids in dyslipidemia [25,26].
In a previous multicenter study we conducted in 2008, it
was found that oral CoA 400 U/d monotherapy effectively
lowered serum TG levels in hypertriglyceridemia patients
without increasing adverse effects when compared with
placebo [27]. So far there has no sufficient clinical research
data to support the efficacy and saftey of oral CoA when
combining used with statin in mixed dyslipidemia patients.
The present study assessed the efficacy and tolerability of
CoA capsule in combination with one stable statin therapy
for lowering TG and other lipid and lipoprotein levels in
patients with mixed dyslipidemia.
Methods
Patients
Eligible patients were male or female between 18 to 80
years of age who had been receiving a normal dose of a
statin (atorvastatin 20 mg/d, rosuvastatin 10 mg/d, simva-
statin 40 mg/d, pravastatin 40 mg/d, pitavastatin 4 mg/d,
fluvastatin 80 mg/d, or lovastatin 40 mg/d) for the control
of LDL-C levels for at least 8 weeks before screening and
had a fasting TG level at 2.3-7.0 mmol/L. Main exclusion
criteria included hepatic dysfunction with elevations of
alanine aminotransferase (SGPT) or aspartate amino-
transferase (SGOT) >2 times the upper limit of normal
(ULN); renal impairment as defined by serum creatin-
ine ≥179 μmol/l; unexplained serum creatine phosphokinase
(CPK) >2 times ULN; poorly controlled hypertension
(resting systolic blood pressure ≥ 180 mmHg and/ordiastolic blood pressure ≥ 110 mmHg at 2 consecutive
visits); pregnancy; breast-feeding; women of childbearing
potential not using chemical or mechanical contraception;
history of alcohol or drug dependence; history of an acute
coronary syndrome within 6 month of screening; uncon-
trolled diabetes; hypothyroidism; New York Heart Associ-
ation class IIIb or IV heart failure or with a left ventricular
ejection fraction known to be <30%; history of receiving
therapies with other non-statin lipid-modifying drugs (e.g.
fibrates, niacin, or fish oils) within 2 months; or history of
adverse events associated with test agents.
Study design
This phase 3, randomized, double-blind, placebo-controlled,
multicenter study was conducted between April 2012
and July 2013 in 10 centers in China. The study con-
sisted of 5 clinic visits: 1 screening visit, 2 visit during
the lead-in/baseling period, and 2 visits during double-
blind treatment. The study protocol and consent form
were reviewed and approved by the appropriate institu-
tional ethics committee at each study site. The study
was conducted in accordance with the Good Clinical
Practice Guidelines, and the Declaration of Helsinki.
Prior to any study procedures, written informed con-
sent was obtained from each study subject by investiga-
tors of each center. The trial has been registered under
Clinical-Trials.gov Identifier NCT01928342 (http://clin-
icaltrials.gov/show/NCT01928342).
At screening (week −4), patients meeting the initial eligi-
bility criteria received the same open-label statin treat-
ment as before with the dosage remaining stable, which
was continued for the remainder of the study. In addition,
they received dietary counseling on the NCEP Therapeutic
Lifestyle Changes diet [28].
After the lead-in phase, patients whose compliance
(measured by the number of capsules consumed relative
to the number expected to be consumed) with statin ther-
apy was ≥80% and who had TG level at 2.3-7.0 mmol/L
with changes in TG levels between weeks −4 and −1 less
than 20% were randomized to receive 8 weeks of double-
blind CoA capsule 400 U/d or placebo (Meiyou Pharma-
ceutical Group Co., Ltd., Shanghai, China). Patients were
allocated numbers as they entered the study, and a
computer-generated randomization scheme was used to
determine treatment allocation as each patient became eli-
gible. Treatment codes for each patient were provided to
each center in a sealed envelope, and investigators were
unaware of the treatment codes until the envelope was
opened at the randomization visit.
Follow-up visits occurred at 4 and 8 weeks after initi-
ation of therapy. A routine physical examination including
height, weight, heart rate, and blood pressure was per-
formed at each visit. Meanwhile, fasting (at least 12 hours)
blood samples were collected. Medication compliance and
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Compliance was assessed using a capsule count at each
visit. The causal relationship of adverse reactions to the
treatment was assessed by the investigators. Education on
healthy lifestyles was reinforced.
Outcome measures and safety assessments
The primary endpoint was the percentage change of
serum TG level from the baseline to the end of treatment.
The secondary endpoint included the percentage changes
from the baseline to the end of treatment in serum TC,
LDL-C, HDL-C, and non-HDL-C levels.
Fasting blood samples were collected at weeks −4, -1, 4,
and 8 for lipid profile and for clinical chemistry (including
SGPT, SGOT, CPK, and serum creatinine) analyses.
Central laboratory was used in the study. All blood sam-
ples were sent to the central laboratory in insulated pack-
aging within 48 hours. Serum lipids were analyzed on a
Hitachi 7600–210 analyzer (Hitachi High-Technologies,
Tokyo, Japan) by a specialist who was unaware of this
study. Other laboratory assessments included hematology
(Sysmex XZ-2100 Hematology Analyzer, Sysmex Medica
Co., Ltd., Hyogo, Japan); chemistry; urinalysis (Aution
Max AX-4280 automated urine test-strip analyzer, ARK-
RAY, Inc., Kyoto, Japan); pregnancy testing for women of
childbearing potential (chemiluminometric immunoassay).
Quality control procedures were applied in line with the
calibration and control requirements specified for each as-
sessment and executed according to Good Laboratory
Practice.Figure 1 Patient disposition throughout the study.Tolerability assessments were based on reported AEs,
physical examinations, and clinical laboratory evaluations
such as liver enzyme elevation >3 × ULN or CPK eleva-
tion >10 ×ULN. The relationship of AEs to the treatment
was assessed (categorized as not related, unlikely, possibly,
probably, or definitely related to study drug). Compliance
was assessed using a capsule count at each visit.
Statistical analyses
On the basis of the results of a phase 2 study [27], an
evaluable sample of 286 (143 per treatment group) was
expected to provide >80% power (2-sided α = 0.05) to
detect a 10% difference in the mean percent change in
TG levels between the 2 treatment groups (assumed
pooled SD, 30%). To account for patient attrition and
noncompliance of 5%, ≥302 patients were expected to be
randomized.
The intent-to-treat (ITT) population included all ran-
domized patients. Efficacy analyses involved all patients in
the ITT population who received at least 1 dose of study
medication and provided at least 1 post-randomization
blood sample. The last-observation-carried-forward (LOCF)
method was used to impute missing nonbaseline data for
patients who did not complete the treatment period. Per-
cent changes from baseline were evaluated by analysis of
variance (ANOVA) with factors fitted for treatment and the
pre-dose (baseline) lipid parameter value as a covariate.
The results were presented as least squares means (LSM)
and the difference between the LSM. Data were analyzed
in SAS/STAT, version 9.13.
Table 1 Demographics and baseline characteristics of
patients in the study population




Age, years 54.8 ± 12.1 53.1 ± 13.1
Sex, n (%)
Male 81 (53.3) 87 (57.2)
Female 71 (46.7) 65 (42.8)
BMI, kg/m2
Male 26.3 ± 2.8 25.5 ± 2.4
Female 24.7 ± 2.9 24.1 ± 2.8
SBP, mmHg 131.4 ± 12.4 128.5 ± 13.9
DBP, mmHg 80.4 ± 9.1 78.1 ± 8.9
Risk factors, n (%)
Type 2 DM 23 (15.1) 28 (18.4)
Hypertension 62 (40.8) 49 (32.2)
Coronary artery disease 18 (11.8) 15 (9.9)
Stroke 3 (2.0) 0 (0)
Medications, n (%)
ACEIs/ARBs 38 (25.0) 27 (17.8)
β-blockers 32 (21.1) 20 (13.2)
Calcium channel blockers 40 (26.3) 24 (15.8)
Diuretics 7 (4.6) 1 (0.7)
Insulin 5 (3.3) 4 (2.6)
Oral hypoglycemic agents 28 (18.4) 26 (17.1)
Platelet aggregation inhibitors 25 (16.4) 18 (11.8)
Organic nitrates 2 (1.3) 3 (2.0)
Statins
Atorvastatin 96 (63.2) 94 (61.8)
Rosuvastatin 12 (7.9) 15 (9.9)
Simvastatin 29 (19.1) 34 (22.4)
Fluvastatin 14 (9.2) 9 (5.9)
Lovastatin 1 (0.7) 0 (0.0)
All values are mean ± standard deviation (SD) unless otherwise specified.
NOTE: CoA = coenzyme A; BMI = body mass index; SBP = systolic blood pressure;
DBP = diastolic blood pressure; DM = diabetes mellitus; ACEI = angiotensin-
converting enzyme inhibitor; ARB = angiotensin receptor blocker.
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study drug and returned to the clinic for at least 1 safety
assessment after randomization were included in the safety
population. The Fisher exact test (2-tailed) was used to
compare the incidence of AEs between treatment groups.
Results
Patient characteristics
Of 667 patients screened, 304 were randomized into the
treatment groups (152 to CoA plus statin, 152 to placebo
plus statin). Three hundred and sixty-three patients were
discontinued before randomization: 328 subjects did not
meet inclusion criteria, 26 withdrew their consents, 7 were
lost to follow-up, and 2 dropped out for adverse events.
The efficacy-evaluable and safety populations included
152 patients in each study group, who received at least
1 dose of the study drug and returned for at least 1
evaluation after randomization (ITT population). Patient
disposition is summarized in Figure 1.
The number of patients completing the study was
comparable in the CoA (144/152 [94.7%]) and placebo
(138/152 [90.8%]) groups. There were 8 non-completes
in the CoA group: 1 patient discontinued due to AE, 5
withdrew consent, and 2 was withdrawn for protocol
violation. There were 14 non-completes in the placebo
group: 3 patients discontinued due to AEs, 8 withdrew
consent, 2 was withdrawn for noncompliance with the
protocol, and 1 was lost to follow-up. For the 22 patients
who withdrew during the double-blind treatment period
after providing at least 1 postrandomization blood sample
for lipid analysis, the LOCF method was used to impute
values for the missing data points.
The efficacy-evaluable and safety populations had a
mean age of 54.0 years and were 55.3% (168/304) male.
Demographics and baseline characteristics of patients in
the study population were demonstrated in Table 1. The
2 groups were comparable in age, sex, body mass index,
blood pressure, risk factors, and medications, including
the types of statins used. With the exception of the TC,
which was significantly higher in the CoA group com-
pared with the placebo group (P = 0.034), there were no
significant differences in any lipid/lipoprotein level be-
tween treatment groups at baseline in the efficacy-
evaluable population.
Efficacy analyses
Changes in regard to lipid end points are presented in
Table 2 and Figure 2. The percent change from baseline
in TG, the primary outcome variable, was significantly
better with CoA plus statin compared with placebo plus
statin (−25.9% vs −4.9%, respectively; p = 0.0003). After
treatment for 8 weeks, the mean percent change in TC
levels was −9.1% in the CoA group, compared with −3.1%
in the placebo group (p = 0.0033). The mean percentchange in LDL-C levels was −9.9% in the CoA group and
0.1% in the placebo group in the end of study (p = 0.003).
HDL-C changed by a mean of 7.9% in the CoA group,
compared with a mean change of 8.2% in the placebo
group (p = 0.94). CoA plus statin was associated with
a mean percent change in non-HDL-C of −13.5% after
8-week treatment, compared with −5.7% in the group
receiving statin plus placebo (p = 0.0039).
Safety analyses
There was no significant difference between groups in
the proportion of patients experiencing AEs (Table 3).
Table 2 Percent change from baseline to study visits in efficacy parameters
Variable Statin + CoA
(n = 152)
Mean percent change,




% ± SE (median)
p value
TG, mmol/L Baseline 3.58 ± 1.26 3.42 ± 1.12
Week 4
2.71 ± 1.70 -24.70 ± 37.69
(-32.69, range -228.83 ~ 90.91)
3.07 ± 1.93 -9.77 ± 48.32
(-16.59, range -245.79 ~ 81.82)
0.0029
Week 8
2.69 ± 2.21 -25.86 ± 50.35
(-36.81, range -386.65 ~ 85.59)
3.23 ± 1.99 -4.87 ± 48.77
(-9.63, range -234.51 ~ 84.49)
0.0003
TC, mmol/L Baseline 5.37 ± 1.17* 5.08 ± 1.22
Week 4 4.84 ± 1.10 -8.22 ± 18.62 (-8.67) 4.78 ± 1.21 -4.66 ± 17.16 (-4.12) 0.085
Week 8 4.79 ± 1.07 -9.13 ± 18.95 (-9.43) 4.86 ± 1.25 -3.13 ± 16.16 (-3.21) 0.0033
HDL-C, mmol/L Baseline 1.20 ± 0.31 1.15 ± 0.30
Week 4 1.24 ± 0.33 6.17 ± 25.87 (1.59) 1.19 ± 0.32 4.86 ± 20.41 (0.00) 0.63
Week 8 1.26 ± 0.36 7.92 ± 28.27 (1.84) 1.23 ± 0.38 8.16 ± 25.87 (1.91) 0.94
LDL-C, mmol/L Baseline 2.91 ± 0.98 2.71 ± 0.92
Week 4 2.61 ± 0.94 -6.35 ± 30.90 (-10.85) 2.57 ± 0.94 -2.51 ± 26.46 (-3.56) 0.25
Week 8 2.53 ± 0.92 -9.90 ± 29.73 (-12.21) 2.63 ± 0.90 0.10 ± 28.28 (-1.46) 0.003
non-HDL-C, mmol/L Baseline 4.18 ± 1.10 3.92 ± 1.16
Week 4 3.60 ± 1.08 -11.64 ± 23.43 (-13.79) 3.59 ± 1.17 -6.61 ± 22.97 (-6.41) 0.06
Week 8 3.53 ± 1.06 -13.45 ± 24.02 (-15.39) 3.64 ± 1.21 -5.73 ± 22.14 (-5.28) 0.0039
All values are mean ± standard deviation (SD) unless otherwise specified.
Note: CoA = coenzyme A; TG = triglyceride; TC = total cholesterol; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol. p values
indicate the percent change between the two groups. *p = 0.034, between-group comparison of baseline TC level.
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the placebo group and no SAE in the CoA group. The
only SAE in the placebo group was a 61-year-old
woman hospitalized for an exacerbation of chest pain
and was not considered by the investigator to be related
to study treatment. The proportion of patients who dis-
continued study treatment because of AEs did not differFigure 2 Mean percent change in triglyceride (TG), total cholesterol (
lipoprotein cholesterol (LDL-C), and non-HDL-C from baseline to the estatistically – in the CoA plus statin group 0.0%, in the
placebo plus statin group 2.6% (Table 3). No AEs involved
myopathy (CPK >10 ×ULN) or rhabdomyolysis. The com-
bination of CoA and statin had no significant effect on
creatinine level during the course of the trial.
There were no cases of clinically significant increases
in hepatic transaminase levels (>3 × ULN) in either group.TC), high-density lipoprotein cholesterol (HDL-C), low-density
nd of treatment. CoA = coenzyme A. *P < 0.01.







Any AE 25 14 11








Abdominal distention 1 1 0
Nausea 2 1 1
Chest pain 1 0 1







Note: CoA = coenzyme A; AE = adverse event.
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vated SGPT in the group that received CoA plus statin
compared with the group that received statin only (0.7%
[1/152] vs 0.0% [0/152], respectively; p = NS). The inci-
dence of mildly elevated CPK was also comparable be-
tween the 2 groups (2.0% [3/152] vs 2.6% [4/152],
respectively; p = NS). The group mean changes from
baseline in SGPT, SPOT, creatinine, and CPK were
small and did not differ between the 2 groups (data not
shown).
Discussion
Hyperlipidemia is an important contributory factor to
development of atherosclerosis, and as such is recog-
nized as a major risk factor for CAD. Consequently, lipid
lowering therapy is very important for the prevention
and treatment of CAD [1,2]. Even though statins are
recommended as first-line drug treatment for patients
with high risk of CAD [29,30], recent studies reported
the importance of lowering serum TG independent of
other lipid variables [6,31,32]. Results from clinical
intervention studies showed that triglyceride lowering
therapies were associated with reduction in non-fatal
MI, revascularization, and all-cause mortality [6]. In 2002,
NCEP ATP III guidelines have identified non-HDL-C as a
secondary treatment target for CAD risk reduction in in-
dividuals with significant evlevations in plasma TG levels
(≥2.26 mmol/L), with a target 0.78 mmol/L higher than
the LDL-C goal [28]. However, hypertriglyceriemia or
non-HDL-C level may not be adequately controlled with
statin monotherapy. Concerning with safety and tolerabil-
ity of TG-lowering agents being used nowadays, especially
in combination therapies, many patients with mixedhyperlipidemia did not achieved combined LDL-C and
non-HDL-C goals [33]. So, safer and better tolerable
agents are being expected to target the residual risk of
hypertriglyceridemia, high non-HDL-C, or low HDL-C
level [24]. The present study investigated the efficacy and
tolerability of coadministration of a new hypolipidemic
agent, CoA with one statin for lowering TG and other li-
poproteins in patients with persistent hypertriglyceridemia
despite statin therapy.
In a previous placebo-controlled trial in patients with
moderate hypertriglyceridemia, administration of CoA
for 8 weeks resulted in 36.1% reduction in TG compared
with placebo (p < 0.0001), without any obviously adverse
effect [27]. In the present study, coadministration of
CoA with statin in patients with hypertriglyceridemia
despite statin therapy was associated with a significantly
greater reductions in TG compared with statin alone
(p < 0.001). CoA was also associated with a significant
reduction in TC, LDL-C and non-HDL-C (all, p < 0.01).
Considering the combined effects of reducing TG and
atherogenic lipoproteins, the addition of CoA to statin
therapy may provide additional clinical benefits in patients
with mixed dylipidemia [4-6,31,34,35].
The mechanism of lipid modifying effects with CoA
has not been elucidated thoroughly. CoA is one of the
most important biologically active compounds which are
essential for metabolism of the three major forms of en-
ergy (fat, carbohydrates, and protein). It presents in all liv-
ing cells that functions as an acyl group carrier and plays a
central role in the tricarboxylic acid cycle (Figure 3). CoA
has a clearly defined role in promoting fat decomposition,
regulating the synthesis of key enzyme of fatty acids
synthetic metabolism, as well as in facilitating fatty acid
β- oxidation. As a cofactor for a number of oxidative
and biosynthetic reactions in intermediary metabolism,
CoA is also involved in the oxidation of fatty acids.
Therefore, it is presume that CoA functions as regulator
on the lipid metabolism, and has a lipid lowering effect
in hyperlipidemia [36].
Previous studies showed that intravenous administration
of CoA could accelerate TG catabolism and thereby lower
TG level by inducing fatty acid oxidation response. It was
suggested that CoA injection could effectively lower post-
prandial serum triglyceride level increasing in patients
with fasting hypertriglyceridemia [23,24]. Although suffi-
cient evidences supported the lipid lowering effect of
CoA, it was inconvenient for patients to receive chronic
intravenous CoA administration. So, oral CoA capsule was
developed. Animal studies showed that fasting TC and
LDL-C levels were significantly reduced with oral CoA ad-
ministration at 800 and 1500 U/kg per day for 20 days,
and TG level was also decreased at a higher dose, suggest-
ing its potential therapeutic role in dyslipidemia [25,26]. In
the previous study, oral CoA 400 U/d effectively lowered
Figure 3 The role of coenzyme A in tricarboxylic acid cycle (citric acid cycle).
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present study confirms the lipid lowering effect of CoA as
reported previously and demonstrated that the combination
of CoA and statin improved the overall lipid profile without
attenuating the efficacy of the statin.
In this study, both treatments were well tolerated.
The incidence and nature of AEs were similar in the 2
treatment groups. The safety profile of CoA administered
with statin was consistent with the known safety profile of
CoA administered alone [27]. In the statin plus CoA
group, the most frequently occurring AEs were upper re-
spiratory tract infection and elevated CPK, none of which
differed significantly from the placebo group. Considering
such AEs were not reported in the previous study with
CoA, and the combining use of statin in this study, the
relationship of elevated CPK or upper respiratory tract
infection to CoA use cannot be finally determined yet.Study limitations
This is the first study to evaluate the efficacy and clinical
safety of CoA capsule combining with statin in subjects
with mixed dyslipidemia. The current study has a few
limitations. The first limitation of this study was the
short duration of double-blind treatment (8 weeks).
Some future studies with longer follow-up duration may
better characterize the long-term efficacy and tolerability
of coadministration of CoA and statin, and the impact of
such coadministration on clinical outcomes. Secondly,
the patients enrolled in this trial are all Chinese subjects, so
the results of this trial may not be directly extrapolated to
other races without any international multicenter clinical
trial result. Finally, although a possible explanation for the
results has been suggested, the underlying mechanism of
the findings cannot be completely clarified by the present
data. However, the elucidation of the exact mechanism of
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hopefully be evaluated by a further investigation.
Conclusions
In the present study, the addition of CoA 400 U/d to
ongoing normal dose of statin was effective in providing
additional lowering of TG, TC, LDL-C, and non-HDL-C
levels in patients with mixed hyperlipidemia. The com-
bination of CoA and statin was well tolerated.
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